{"entity":{"id":"nct00880269","kind":"trial","name":"Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","aka":[],"tldr":"A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.","summary":"Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) is a phase 2 interventional study registered as NCT00880269 by Novartis Pharmaceuticals, with 59 participants recorded, started 2009-08 and reaching its primary completion in 2012-02. Interventions recorded: Panobinostat/LBH589. Conditions recorded: Refractory Leukemia, Acute Myelogenous Leukemia.\n\nLinked to the drug Panobinostat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00880269","url":"https://clinicaltrials.gov/study/NCT00880269"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["panobinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00880269","phase":"2","setting":"A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","sponsor":"Novartis Pharmaceuticals","enrolled":59,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00880269/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/"}]}}